Wu Liu1,2, Jenna May Kim3, Benjamin K Young3, Ravinder Nath1,2, Zhe Chen1,2, Roy H Decker1,2, Melvin A Astrahan4, Renelle Pointdujour-Lim3,2. 1. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut, USA. 2. Yale Smilow Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA. 3. Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut, USA. 4. Eye Physics LL, Los Alamitos, California, USA.
Abstract
BACKGROUND: While traditional eye plaque brachytherapy can be used for the treatment of iris melanoma, it faces challenges of poor patient tolerability due to cornea-plaque touch caused by radius of curvature mismatch and potential dosimetric inaccuracy from incomplete coverage. We present novel plaque designs and the first clinical application of the plaques for iris melanoma. METHODS: Two dome-shaped plaques (EP2132 and EP1930) were designed to vault above the cornea to treat tumors of the iris and ciliary body. Image-based treatment planning of the first 2 clinical cases using the EP2132 plaque covered the tumor base plus a 2 mm margin and the involved ciliary body with at least 75 Gy to the tumor apex. RESULTS: The tumors decreased in size following treatment. The patients tolerated the treatment well. There was no adverse event associated with the traditional iris plaques, such as decreased vision, pain, corneal edema, glaucoma, or cataract. CONCLUSION: The novel dome-shaped plaques for the treatment of iris melanoma provide effective dose distribution, improved surgical maneuverability, and increased tolerability for the patient. This plaque model can be used to treat iris melanoma of various sizes, configurations, and locations, including the ciliary body. The need for a customized plaque platform for each patient is minimized.
BACKGROUND: While traditional eye plaque brachytherapy can be used for the treatment of iris melanoma, it faces challenges of poor patient tolerability due to cornea-plaque touch caused by radius of curvature mismatch and potential dosimetric inaccuracy from incomplete coverage. We present novel plaque designs and the first clinical application of the plaques for iris melanoma. METHODS: Two dome-shaped plaques (EP2132 and EP1930) were designed to vault above the cornea to treat tumors of the iris and ciliary body. Image-based treatment planning of the first 2 clinical cases using the EP2132 plaque covered the tumor base plus a 2 mm margin and the involved ciliary body with at least 75 Gy to the tumor apex. RESULTS: The tumors decreased in size following treatment. The patients tolerated the treatment well. There was no adverse event associated with the traditional iris plaques, such as decreased vision, pain, corneal edema, glaucoma, or cataract. CONCLUSION: The novel dome-shaped plaques for the treatment of iris melanoma provide effective dose distribution, improved surgical maneuverability, and increased tolerability for the patient. This plaque model can be used to treat iris melanoma of various sizes, configurations, and locations, including the ciliary body. The need for a customized plaque platform for each patient is minimized.
Authors: Rowan M Thomson; Keith M Furutani; Jose S Pulido; Scott L Stafford; D W O Rogers Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-14 Impact factor: 7.038
Authors: Samira Khan; Paul T Finger; Guo-Pei Yu; Lubna Razzaq; Martine J Jager; Rob J W de Keizer; Per Sandkull; Stefan Seregard; Daniel Gologorsky; Amy C Schefler; Timothy G Murray; Tero Kivelä; Gian Paolo Giuliari; Hugh McGowan; E Rand Simpson; Christine Corriveau; Sarah E Coupland; Bertil E Damato Journal: Arch Ophthalmol Date: 2011-09-12
Authors: Carol L Shields; Masood Naseripour; Jerry A Shields; Jorge Freire; Jacqueline Cater Journal: Am J Ophthalmol Date: 2003-05 Impact factor: 5.258